Evidence map›Paper›PMID 28192085›Full record

ArticleBiochemical pharmacology2017

Influence of peptide transporter 2 (PEPT2) on the distribution of cefadroxil in mouse brain: A microdialysis study.

Xiaomei Chen, Richard F Keep, Yan Liang, Hao-Jie Zhu, Margareta Hammarlund-Udenaes, Yongjun Hu, David E Smith

Abstract read
In one paragraph

Article in Biochemical pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Revisiting atenolol as a low passive permeability marker.Fluids and barriers of the CNS · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Xiaomei ChenDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, MI, USA. Electronic address: xmchen@umich.edu.
Richard F KeepDepartment of Neurosurgery, University of Michigan Health System, Ann Arbor, MI, USA. Electronic address: rkeep@umich.edu.
Yan LiangDepartment of Clinical Pharmacy, College of Pharmacy, University of Michigan, Ann Arbor, MI, USA. Electronic address: liangyan0679@hotmail.com.
Hao-Jie ZhuDepartment of Clinical Pharmacy, College of Pharmacy, University of Michigan, Ann Arbor, MI, USA. Electronic address: hjzhu@med.umich.edu.
Margareta Hammarlund-UdenaesDepartment of Pharmaceutical Biosciences, Translational PKPD Research Group, Uppsala University, Uppsala, Sweden. Electronic address: mhu@farmbio.uu.se.
Yongjun HuDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, MI, USA. Electronic address: yongjun@umich.edu.
David E SmithDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, MI, USA. Electronic address: smithb@umich.edu.
University of Michigan–Ann Arbor · USMichigan Medicine · USUppsala University · SE

Funding

Novel Transport and Activation Strategy to Improve the Bioavailability of Targeted ProdrugsR01GM115481 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI AMIDON, GORDON L, SMITH, DAVID E · 2015 to 2018
$1.7M
NIGMS NIH HHS R01 GM115481
6 · The paper itself

Abstract

Peptide transporter 2 (PEPT2) is a high-affinity low-capacity transporter belonging to the proton-coupled oligopeptide transporter family. Although many aspects of PEPT2 structure-function are known, including its localization in choroid plexus and neurons, its regional activity in brain, especially extracellular fluid (ECF), is uncertain. In this study, the pharmacokinetics and regional brain distribution of cefadroxil, a β-lactam antibiotic and PEPT2 substrate, were investigated in wildtype and Pept2 null mice using in vivo intracerebral microdialysis. Cefadroxil was infused intravenously over 4h at 0.15mg/min/kg, and samples obtained from plasma, brain ECF, cerebrospinal fluid (CSF) and brain tissue. A permeability-surface area experiment was also performed in which 0.15mg/min/kg cefadroxil was infused intravenously for 10min, and samples obtained from plasma and brain tissues. Our results showed that PEPT2 ablation significantly increased the brain ECF and CSF levels of cefadroxil (2- to 2.5-fold). In contrast, there were no significant differences between wildtype and Pept2 null mice in the amount of cefadroxil in brain cells. The unbound volume of distribution of cefadroxil in brain was 60% lower in Pept2 null mice indicating an uptake function for PEPT2 in brain cells. Finally, PEPT2 did not affect the influx clearance of cefadroxil, thereby, ruling out differences between the two genotypes in drug entry across the blood-brain barriers. These findings demonstrate, for the first time, the impact of PEPT2 on brain ECF as well as the known role of PEPT2 in removing peptide-like drugs, such as cefadroxil, from the CSF to blood.

Indexed as

AnimalsAnti-Bacterial AgentsBrainCefadroxilMiceMice, KnockoutMicrodialysisSymportersAnti-Bacterial AgentsCefadroxilhydrogen-coupled oligopeptide transporter PepT2SymportersBlood-cerebrospinal fluid barrierBrain extracellular fluidCefadroxilMicrodialysisPeptide transporter 2

Identifiers

PMID28192085
PMCPMC5365381
OpenAlexW2587584306

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.